Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$130.86 - $143.19 $385,382 - $421,694
-2,945 Reduced 42.93%
3,915 $538,000
Q1 2024

May 15, 2024

BUY
$130.4 - $143.74 $894,544 - $986,056
6,860 New
6,860 $946,000
Q1 2022

May 16, 2022

BUY
$72.45 - $94.81 $16,735 - $21,901
231 Added 5.09%
4,768 $441,000
Q3 2021

Nov 12, 2021

BUY
$86.18 - $99.03 $130,821 - $150,327
1,518 Added 50.28%
4,537 $428,000
Q2 2021

Aug 06, 2021

BUY
$89.43 - $102.27 $41,227 - $47,146
461 Added 18.02%
3,019 $293,000
Q1 2021

May 14, 2021

SELL
$87.57 - $119.4 $287,842 - $392,467
-3,287 Reduced 56.24%
2,558 $241,000
Q4 2020

Feb 12, 2021

SELL
$86.91 - $108.33 $49,277 - $61,423
-567 Reduced 8.84%
5,845 $558,000
Q3 2020

Nov 13, 2020

SELL
$96.16 - $135.15 $186,550 - $262,191
-1,940 Reduced 23.23%
6,412 $626,000
Q1 2020

May 11, 2020

BUY
$75.11 - $113.76 $277,306 - $420,001
3,692 Added 79.23%
8,352 $765,000
Q4 2018

Feb 14, 2019

SELL
$68.32 - $124.36 $474,140 - $863,058
-6,940 Reduced 59.83%
4,660 $319,000
Q3 2018

Nov 14, 2018

BUY
$98.88 - $125.85 $1.15 Million - $1.46 Million
11,600 New
11,600 $1.43 Million

Others Institutions Holding NBIX

About NEUROCRINE BIOSCIENCES INC


  • Ticker NBIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 95,639,296
  • Market Cap $12B
  • Description
  • Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...
More about NBIX
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.